Apart from the existent surgery, radiotherapy, chemotherapeutic drugs, or even some newly emergent cancer treatment, such as the revolutionary use of CRISPR/Cas 9 clinically, delivery of engineered cytotoxic T cells (CAR-T) targeting tumor antigens [114], clinical use of antibodies targeting immune checkpoint blockade like cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1) [115], we boldly speculate a new therapeutic mode and describe it as ‘two-compartment blockade’. This evidence concerns the gene CTLA4 and cancer.